Physician profile
Leon A Feldman
NPI 1003876418
$303,088.72
in general payments reported to CMS, 2019-2025
26 companies · $8,820 in 2025
The $8,820 reported for 2025 was more than what 78% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $93K · 2021: $18K · 2022: $6,597 · 2023: $25K · 2024: $8,277 · 2025: $8,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $8,382 · Food and Beverage: $7,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,630.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,400.00 |
| Travel and Lodging | $8,382.13 |
| Food and Beverage | $7,617.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $165,691.29 | 2019-2022 | |
| Abbott Laboratories | $74,325.00 | 2019-2025 | Aveir, Amplatzer, Amplatzer Amulet |
| Medtronic, INC. | $23,899.23 | 2021-2025 | Micra, Evera Mri Xt Dr Surescan, Aurora Ev-Icd Mri Surescan |
| Avertix Medical, INC | $15,630.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $4,758.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,707.53 | 2019-2020 | |
| Boston Scientific Corporation | $4,543.69 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $4,379.43 | 2019-2020 | |
| Pfizer INC. | $2,525.00 | 2019 | |
| Biotronik INC. | $630.68 | 2019-2023 | Acticor 7 Vr-T Dx |
| Impulse Dynamics (USA) INC. | $531.02 | 2025 | Optimizer |
| Atricure, INC. | $275.02 | 2022-2024 | |
| Cardiofocus, INC. | $212.61 | 2019 | |
| Siemens Medical Solutions USA, INC. | $169.69 | 2023 | Artis Icono Floor |
| Abiomed | $157.48 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $100.48 | 2021-2023 | |
| Philips North America LLC | $100.24 | 2020-2024 | (Bs2) Lm Undivided |
| Edwards Lifesciences Corporation | $93.54 | 2023 | Sapien 3 Ultra Resilia |
| Cordis US Corp. | $81.62 | 2024-2025 | Mynx Control Venous, Mynx Control |
| Davol INC. | $76.20 | 2021 | |
| Medtronic Vascular, INC. | $58.72 | 2019-2020 | |
| Baxter Healthcare | $51.22 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Endotronix, INC. | $49.31 | 2021-2022 | |
| Elutia, INC. | $15.81 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.16 | 2022-2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.